Show Notes
In this episode of The Good GP, host Dr Krystyna De Lange speaks with Dr David Leitinger, a GP with a special interest in addiction medicine, about the practical use of naltrexone for managing alcohol use disorder (AUD).
Dr Leitinger explains how naltrexone, an opioid antagonist, disrupts the endorphin-mediated reward of alcohol consumption, helping patients gradually reduce intake and unlearn habitual drinking behaviours. He highlights that naltrexone can be prescribed while patients are still drinking, not only during abstinence, and discusses flexible prescribing methods including daily dosing and the “Sinclair Method” of targeted dosing prior to drinking.
Important considerations covered include contraindications such as concurrent opioid use and the approach to temporary cessation if opioid analgesia is needed. Dr Leitinger reassures that naltrexone is generally safe in patients with liver disease and recommends baseline and follow-up LFTs, though testing should not be a barrier to therapy.
A case study illustrates practical patient outcomes, expectations, and follow-up. Strategies for supporting patients through lapses and individualising success measures are discussed, as well as where naltrexone fits alongside other first-line options like acamprosate. The value of harm reduction and ongoing patient support in primary care is emphasised.
Link & Resources: AJGP article on naltrexone in alcohol use disorder: https://www1.racgp.org.au/ajgp/2026/january-february/naltrexone Community Access to Pharmacotherapy for Alcohol (CAPA) EOI Form: https://forms.cloud.microsoft/Pages/ResponsePage.aspx?id=xMYIFZVfdU-KZ5mS34Mn6CJfQHBGKCREk2C2wuYgdyNUM0IzSDc4WTVXMkNGT1VXWkYxMlNGQ0FIVy4u&origin=QRCode A 2-step reduction in WHO alcohol risk drinking levels (rather than abstinence) for harm reduction: https://pmc.ncbi.nlm.nih.gov/articles/PMC12739655/ Stronger evidence for the effectiveness of naltrexone: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2727384
The Good GP Podcast is a proud member of the Talking HealthTech Podcast Network - the premier audio destination for cutting-edge insights and thought leadership in healthcare delivery, innovation, digital health, healthcare ICT, and commercialisation. Learn more at www.talkinghealthtech.com/podcast/network
If you have any questions or would like to contact The Good GP, send an email to [email protected]. Visit www.thegoodgp.com.au for previous episodes and more information. You can also find us on our Instagram page: @thegoodgppodcast. Follow us for more updates!
More from The Good GP
In this episode of The Good GP, Dr Krystyna de Lange speaks with Dr Steph Daly, GP with a special interest in aged care and dementia, about the introduction of plasma biomarkers, specifically the p-Tau 217 blood test for Alzheimer’s disease. They explore what the p-Tau 217 test measures, its reliability, and its role in primary care.
In this episode of The Good GP, Dr Julia Rawlinson speaks with Dr Florence Martin, an epidemiologist specialising in pregnancy pharmacoepidemiology. Dr Martin discusses her recent study examining the relationship between first trimester antidepressant use and miscarriage risk, using UK primary care data from the CPRD GOLD database.
In this episode of the Good GP, Dr Julia Rawlinson speaks with Dr Julia Feutrill, consultant psychiatrist at King Edward Memorial Hospital and co-director of the Elizabeth Clinic. They discuss the complexities of antidepressant use during pregnancy, providing GPs with practical advice for navigating these conversations.
In this episode of the Good GP, Dr Julia Rawlinson speaks with Dr Paul Effler, Senior Medical Advisor at the WA Department of Health and expert in communicable diseases, about H5N1 avian influenza and pertussis.
In this episode, Dr Julia Rawlinson is once again joined by Dr Emma Turner, Paediatric Gastroenterologist and Hepatologist at Perth Children’s Hospital, and Dr Erin Horsley, GP Anaesthetist with a special interest in gastroenterology and lived experience parenting a child with coeliac disease. For the second part of their discussion on coeliac disease in children.